Copyright
©14 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 15992-16013
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15992
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15992
Drug target | DAA agents | RAV |
NS3/4A protease | ||
Telaprevir | V36M/A1, T54A/S1, R155K/T1, A156S/T/V1 | |
Boceprevir | V36M/A1, T54A/S1, V55A1, R155K/T1, A156S/T/V1, V158I, V170A, M175L | |
Faldaprevir | R155K1, A156T/V, D168V/E1 | |
Simeprevir | V36M, F43S, Q80K1, S122A/R, R155K1, A156T/V, D168V/E1, I170T | |
ABT-450 | V36M/A/G, V55I, R155K1, A156T/V, D168A/V1 | |
Danoprevir | V36M/A, V55I, R155K1, D168E/T1 | |
Vaniprevir | R155G1/K/N/S/T, A156V, D168V1/G/A | |
NS5B polymerase | ||
Mericitabine | S282T, L159F, L320F | |
BI 207127 | P495L1/S/A/T/Q, P496S, V499A | |
Lomibuvir/VX-222 | L419S1, R422K1, M423TV | |
Setrobuvir | M414T/L, G554D, D559G | |
NS5A | ||
Daclatasvir | M28V/A/T, Q30R/E/H, L31V/M1, Q54H/N/Y, H58D, Q62R/E, A92K/T, Y93H/N/C1 |
- Citation: Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/15992.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.15992